What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how...
Last week we posted an analysis of the growth rates and market caps for companies that develop IVD tests (which was in itself a follow-up to some analyses from a couple of years ago). This week we are presenting the same analysis for developers of lab-developed tests...
In mid-2015 we worked hard to add a new source of evidence for biomarkers: Laboratory Developed Tests, or LDTs. This was a huge milestone for Amplion. We successfully used our technology to identify biomarkers in a new information source very quickly without...
At Amplion we have a commercial interest in access to high quality clinical information that can inform and contribute to our flagship product, BiomarkerBase. However, we are truly passionate about contributing to higher quality, more personalized, medical...
The Promise of Personalized Medicine The team at Amplion is dedicated to seeing the promise of personalized medicine fully realized. And although we all come from diverse backgrounds, we’re fired up and fully invested in contributing to that promise becoming a...
